Premium
Atrial fibrillation in hospitalized patients with end‐stage liver disease: temporal trends in prevalence and outcomes
Author(s) -
Han Hedong,
Qin Yingyi,
Yu Yamei,
Wei Xin,
Guo Honglei,
Ruan Yiming,
Cao Yang,
He Jia
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14291
Subject(s) - medicine , atrial fibrillation , odds ratio , confidence interval , liver disease , healthcare cost and utilization project , emergency medicine , intensive care medicine , health care , economics , economic growth
Abstract Background & Aims End‐stage liver disease (ESLD) happens due to the development and progression of chronic liver disease. This study aims to investigate the temporal trend, patient characteristics and outcomes of atrial fibrillation (AF) in hospitalized ESLD patients across the United States. Methods Nationwide Inpatient Sample from 2003 to 2014 was utilized to retrospectively study the weighted prevalence of AF in hospitalized ESLD patients. Multivariable regression models were used to assess the association between AF with clinical factors, in‐hospital mortality, length of stay (LOS) and cost. Results 639 345 hospitalizations associated with ESLD were identified, of which 47 710 (7.48%) were diagnosed with AF. The prevalence of AF increased from 5.73% in 2003 to 9.75% in 2014 in ESLD and varied by age, race, income, insurance type and hospital characteristics. Factors associated with AF included advancing age, male, white race, high income and urban teaching hospital. AF presence was associated with significant higher in‐hospital mortality (odds ratio, 1.40; 95% confidence interval, 1.35‐1.45), 21% longer LOS and 22% higher cost. In addition, a significant decreasing trend in in‐hospital mortality was observed (from 16.70% to 10.63% in patients with AF and from 10.74% to 7.50% in patients without AF). Conclusions The prevalence of AF in hospitalized ESLD patients has continued to increase from 2003 through 2014. AF is associated with poor prognosis and higher health resource utilization. Innovative anticoagulation strategies through improved collaboration between cardiologists and hepatologists are required for better management of hospitalized ESLD patients comorbid with AF.